COMMUNIQUÉS West-GlobeNewswire

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
06/03/2024
Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team
06/03/2024
BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS- [...]
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
06/03/2024
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, March 06, [...]
Health technology leader Philips recognized as Clarivate Top 100 Global Innovator
06/03/2024
March 6, 2024 Company’s innovative products and solutions improved the lives of 1.9 billion people in 2023 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has [...]
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
06/03/2024
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17 th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2 Diabetes Patients in [...]
VALNEVA Declaration of shares and voting rights - February 29, 2024
06/03/2024
VALNEVA Declaration of shares and voting rights February 29, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
Déclaration d’actions et de droits de vote de la société Valneva - 29 février 2024
06/03/2024
VALNEVA Déclaration d’actions et de droits de vote 29 février 2024 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
Virbac to take a leading position in Japan through the acquisition of Sasaeah
06/03/2024
Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million. Formed through the [...]
Virbac prend une position de leader au Japon grâce à l'acquisition de Sasaeah
06/03/2024
Virbac annonce la signature d'un accord définitif avec ORIX Corporation pour l'acquisition de sa filiale de santé animale Sasaeah pour une valeur d'entreprise d'environ 280 millions d'euros. Issue du regroupement de [...]
Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
06/03/2024
Tokyo, Japan and Cambridge, UK, 6 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. (“Formosa”) has received approval from the US Food [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
06/03/2024
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial [...]
Bavarian Nordic Publishes Annual Report 2023
06/03/2024
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced on February 21, [...]
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
06/03/2024
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the [...]
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
06/03/2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked [...]
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
06/03/2024
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology PHILADELPHIA, [...]
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
05/03/2024
Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, [...]
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
05/03/2024
CBX-250 is a first-in-class, potent, and specific T-cell engager for the treatment of myeloid leukemia Abstract summarizing preclinical characteristics of CBX-250 selected for an oral presentation at the American [...]
Opthea to Participate in the Leerink Partners Global Biopharma Conference
05/03/2024
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive [...]
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
05/03/2024
Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million Reaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024 [...]

Pages